Your browser doesn't support javascript.
loading
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
Rugo, Hope S; Tolaney, Sara M; Loirat, Delphine; Punie, Kevin; Bardia, Aditya; Hurvitz, Sara A; O'Shaughnessy, Joyce; Cortés, Javier; Diéras, Véronique; Carey, Lisa A; Gianni, Luca; Piccart, Martine J; Loibl, Sibylle; Goldenberg, David M; Hong, Quan; Olivo, Martin; Itri, Loretta M; Kalinsky, Kevin.
Afiliación
  • Rugo HS; Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. Hope.Rugo@ucsf.edu.
  • Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Loirat D; Department of Medical Oncology and D3i, Institut Curie, Paris, France.
  • Punie K; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
  • Bardia A; Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Hurvitz SA; Medical Oncology, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
  • O'Shaughnessy J; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA.
  • Cortés J; International Breast Cancer Center (IBCC), Quiron Group, Madrid & Barcelona, Barcelona, Spain.
  • Diéras V; Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Carey LA; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain.
  • Gianni L; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
  • Piccart MJ; Department of Hematology and Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
  • Loibl S; Gianni Bonadonna Foundation, Milano, Italy.
  • Goldenberg DM; Medical Oncology, Institute Jules Bordet, Brussels, Belgium.
  • Hong Q; Department of Medicine and Research, Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany.
  • Olivo M; Department of Clinical Development, Immunomedics, Inc., Morris Plains, NJ, USA.
  • Itri LM; Department of Clinical Development, Immunomedics, Inc., Morris Plains, NJ, USA.
  • Kalinsky K; Department of Clinical Development, Immunomedics, Inc., Morris Plains, NJ, USA.
NPJ Breast Cancer ; 10(1): 41, 2024 Jun 06.
Article en En | MEDLINE | ID: mdl-38844800
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Breast Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Breast Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos